Known as one of the most headstrong investors on Wall Street, activist investor William A. Ackman announced a joint bid with pharmaceutical company Valeant to acquire Botox maker Allergan in a $50 billion deal, say reports.
If successful, the transaction could usher in a new era for how acquisitions are made, reports say. The proposed deal is the first of its kind.
Ackman has slowly been acquiring Allergan shares through his Pershing Square Capital Management. Canada-based Valeant has reportedly agreed to pursue a takeover and contributed $76 million to Pershing Square’s PS Fund 1, according to regulatory filings.
The joint pursuit of an investor and corporation could signal change in how the two groups work together, reports say, but also raises some concern over conflicts of interest.
Full Content: DealBook
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Athletes Behind NCAA Antitrust Settlement Push for Collective Bargaining Rights
Dec 11, 2024 by
CPI
Big Tech Stocks Surge as Trump Names Ferguson to Lead FTC
Dec 11, 2024 by
CPI
Synopsys Proposes Divestitures to Secure EU Approval for $35 Billion Ansys Deal
Dec 11, 2024 by
CPI
Renowned Antitrust Expert and Former Morgan Lewis Chair John Shenefield Passes Away
Dec 11, 2024 by
CPI
Trump Taps Mark Meador for Federal Trade Commission Post
Dec 11, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Moats & Entrenchment
Nov 29, 2024 by
CPI
Assessing the Potential for Antitrust Moats and Trenches in the Generative AI Industry
Nov 29, 2024 by
Allison Holt, Sushrut Jain & Ashley Zhou
How SEP Hold-up Can Lead to Entrenchment
Nov 29, 2024 by
Jay Jurata, Elena Kamenir & Christie Boyden
The Role of Moats in Unlocking Economic Growth
Nov 29, 2024 by
CPI
Overcoming Moats and Entrenchment: Disruptive Innovation in Generative AI May Be More Successful than Regulation
Nov 29, 2024 by
Simon Chisholm & Charlie Whitehead